Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Adrian Cook"'
Autor:
R. Roux, C. Butcher, G. Bertelli, Rosemary Lord, R.M. Glasspool, Shibani Nicum, Adrian Cook, Michelle Ferguson, Melanie Mackean, M. Martinez, S. Love, L. Howells, Christina Fotopoulou, Eleni Frangou, Sarah P. Blagden, Nicholas J. Hulbert-Williams
Publikováno v:
Gynecologic Oncology. 162:431-439
Background Fear of disease progression (FOP) is a rational concern for women with Ovarian Cancer (OC) and depression is also common. To date there have been no randomized trials assessing the impact of psychological intervention on depression and FOP
Autor:
Noel W. Clarke, Claire Amos, Hassan Douis, Nicholas D. James, Gerhardt Attard, Malcolm David Mason, Mahesh K. B. Parmar, Adrian Cook, Chris Parker, Alex Hoyle, J. Calvert, Christopher D. Brawley, Adnan Ali, Matthew R. Sydes
Publikováno v:
Ali, A, Hoyle, A, Parker, C C, Brawley, C D, Cook, A, Amos, C, Calvert, J, Douis, H, Mason, M D, Attard, G, Parmar, M K B, Sydes, M R, James, N D & Clarke, N 2020, ' The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer : An Exploratory Analysis of STAMPEDE’s “M1|RT Comparison” ', European Urology Oncology . https://doi.org/10.1016/j.euo.2020.05.003
European Urology Oncology
European Urology Oncology
Background Prostate radiotherapy (RT) is a first-line option for newly diagnosed men with low-burden metastatic prostate cancer. The current criterion to define this clinical state is based on manual bone metastasis counts, but enumeration of bone me
Autor:
Timothy J. Perren, Rosemary Lord, Jane Hook, Ian A. McNeish, Christopher J. Poole, Jonathan A. Ledermann, Helena M. Earl, Sarah P. Blagden, Adrian Cook, Jae Weon Kim, Graham Dark, Andrew R Clamp, Marcia Hall, Dearbhaile M. O'Donnell, Richard Kaplan, Ian R. White, Lesley Howells, Andrew Dean, Elizabeth C. James
Publikováno v:
Lancet Oncol
The Lancet. Oncology
The Lancet. Oncology
Summary Background The ICON8 study reported no significant improvement in progression-free survival (a primary endpoint) with weekly chemotherapy compared with standard 3-weekly treatment among patients with epithelial ovarian cancer. All ICON8 patie
Autor:
Hani Gabra, Dearbhaile M. O'Donnell, S. P. Stenning, Christopher Coyle, Jane Hook, Rosalind Glasspool, Graham Dark, Rachel Jones, Susana Banerjee, Jonathan A. Ledermann, Helena M. Earl, Andrew R Clamp, Adrian Cook, Marcia Hall, Timothy J. Perren, Sarah Williams, Rosemary Lord, Mahesh K. B. Parmar, Gosala S. Gopalakrishnan, Ann Marie Swart, Jae Weon Kim, Sudha Sundar, James D. Brenton, Elizabeth C. James, Raj Naik, Richard Kaplan, Iain A. McNeish, Andrew Dean, Sarah P. Blagden
Publikováno v:
Lancet (London, England)
Background:\ud Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a significant improvement in progression-free and overall survival with
Autor:
Andrew R Clamp, Sharadah Essapen, Adrian Cook, Marcia Hall, Elizabeth C. James, Sarah Williams, Jonathan A. Ledermann, Kate Scatchard, Jae Weon Kim, Jonathan Krell, Abel Zachariah, Gordon C Jayson, Iain A. McNeish, Axel Walther, Anjana Anand, Rachel Jones, Sudha Sundar, Christine Parkinson, Jeff Summers, Robert D. Morgan, Dolores Gallardo-Rincón, Christopher J. Poole, Graham Dark, Rosemary Lord, Rosalind Glasspool, Michelle Lockley
Publikováno v:
The Lancet. Oncology. 22(2)
Summary Background Platinum-based neoadjuvant chemotherapy followed by delayed primary surgery (DPS) is an established strategy for women with newly diagnosed, advanced-stage epithelial ovarian cancer. Although this therapeutic approach has been vali
Autor:
Chee Goh, Peter Cooke, Anjali Zarkar, Holly Pickering, Noel W. Clarke, Julian Money-Kyrle, Henriette Lindberg, Wendy R. Parulekar, Klaus Brasso, Mahesh K. B. Parmar, Martin Andreas Røder, Jason F. Lester, S L Morris, Nicholas D. James, Amit Bahl, Rajendra Persad, William Cross, Stephanie Gibbs, Charles Catton, Henrik Jakobsen, Peter Ostler, Rakesh Raman, James M. Wilson, Ian Sayers, Matthew R. Sydes, Ramasamy Jaganathan, Heather Payne, Lisa Owen, Howard Kynaston, Joe M. O'Sullivan, Adrian Cook, Sandeep Gujral, Alvan Pope, Ben Eddy, Chris Parker, Matthew S. Simms, Juliette Anderson, Rick Popert, Prashant Patel, Alastair Henderson, David Bottomley, John P Logue, Peter Meidahl Petersen, Fred Saad, Kathryn Lees, Rohit Chahal, Catherine Heath, S.K. Sundaram
Publikováno v:
Lancet (London, England). 396(10260)
Summary Background The optimal timing of radiotherapy after radical prostatectomy for prostate cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy versus an observation policy with salvage radiotherapy for prosta
Autor:
Janet E. Brown, J.M. Russell, Hassan Douis, Adrian Cook, Matthew R. Sydes, David Matheson, Narayanan Srihari, Alex Hoyle, Matthew S. Simms, A. Nikapota, Anjali Zarkar, Christopher D. Brawley, F.C. Ingleby, Noel W. Clarke, J. Calvert, John Wagstaff, Duncan C. Gilbert, Gerhardt Attard, Jacob Tanguay, A.W.S. Ritchie, Adnan Ali, Ruth E Langley, Andrew Protheroe, Aurelius Omlin, H. Rush, Anna Lydon, David P. Dearnaley, Malcolm David Mason, James D. Wylie, Silke Gillessen, Simon Chowdhury, L. Capaldi, Sharon Beesley, Joe M O'Sullivan, Mona Parmar, Omi Parikh, Joanna Gale, Jan Wallace, S. Rudman, Chris Parker, Alison Birtle, Archie Macnair, Claire Amos, Stephanie Gibbs, Robin Millman, Robert Jones, Zafar Malik, William Cross, Nicholas D. James, Shaun Tolan
Publikováno v:
STAMPEDE Investigators 2019, ' Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial ', Annals of Oncology . https://doi.org/10.1093/annonc/mdz396
Annals of Oncology
Annals of Oncology
Background\ud \ud STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae50219cab2735395675e6bd870c6e64
https://doi.org/10.1093/annonc/mdz396
https://doi.org/10.1093/annonc/mdz396
Autor:
Laura Farrelly, Mahesh K.B. Parmar, Gordon J. S. Rustin, Richard Kaplan, Ann Marie Swart, Elizabeth Eisenhauer, Stan B. Kaye, Fharat A. Raja, Michael Friedlander, Dan Stark, Hal W. Hirte, Elizabeth Clark, Timothy J. Perren, Adrian Cook, Jonathan A. Ledermann, Andrew C. Embleton, Gordon C Jayson, Antonio González-Martín, Michelle D. Vaughan
SummaryBackgroundAngiogenesis is a validated clinical target in advanced epithelial ovarian cancer. Cediranib is an oral antiangiogenic vascular endothelial growth factor receptor 1–3 inhibitor that has shown antitumour activity in recurrent ovaria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6c728f51b9da1b574006964d10f7f81
https://ueaeprints.uea.ac.uk/id/eprint/58290/
https://ueaeprints.uea.ac.uk/id/eprint/58290/
Publikováno v:
Public Health Nutrition. 4:787-795
Objectives:Using a national representative sample to identify groups within the UK male and female population over 65 years who report similar patterns of diet.Design:National representative dietary survey, using 4-day weighed dietary records of men
Publikováno v:
Journal of evaluation in clinical practice. 11(2)
Objective To determine the effects of community based nurses specialising in Parkinson's disease on health outcomes and healthcare costs. Design Two year randomised controlled trial in 438 general practices in nine randomly selected health authority